Cobimetinib and pancreatic cancer

October 17, 2025Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Based on the provided NCCN Guidelines excerpts, I cannot make any specific claims about cobimetinib and pancreatic cancer. While cobimetinib is mentioned in the guidelines, it is only discussed in combination with vemurafenib as a treatment for melanoma with BRAF V600 mutations (as shown in Guide 16 of the NCCN Guidelines).

According to the guidelines, pancreatic cancer is only mentioned in the context of:

  1. Being a potential associated cancer in families with hereditary melanoma risk
  2. The recommendation that "Multigene panel testing that includes CDKN2A may also be recommended if you have a relative diagnosed with pancreatic cancer"

For accurate information about cobimetinib and pancreatic cancer, I recommend:

  1. Consulting with your healthcare provider
  2. Checking current FDA approvals
  3. Reviewing NCCN Guidelines specific to pancreatic cancer (which are not included in the provided excerpts)

Always discuss any treatment decisions with your healthcare team, as they can provide guidance based on your specific medical situation and current clinical evidence.

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: